Zhejiang pharma maker known for a fungal-fermentation traditional medicine capsule used to treat insomnia and fatigue.
Zhejiang pharma maker known for a fungal-fermentation traditional medicine capsule used to treat insomnia and fatigue.
One capsule product carries most sales, sold mainly through hospital prescriptions and pharmacies, so reimbursement listing and prescriber habits matter more than the rest of the range.
In one line: A small, single-product Chinese sleep-aid drugmaker.
Moat: narrow (brand, IP / patents). Patented fermentation process and an established brand in a niche TCM sleep-aid category.
Headquarters: Huzhou, Zhejiang, China · Employees: 2,861
Size Zhejiang Jolly Pharmaceutical (300181.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.34B, the 1679th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.64 on 18 Nov 2026.
Performance Over six months the shares fell 14.7%, against -17.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.
Growth Revenue grew 16.6% over the last twelve months (peer median +9.2%); the operating margin is 19.7% (peer median -1.9%).
Valuation It trades at 13.0× forward earnings against a peer median of 20.4× (5th cheapest of 11).
Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -19 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 6.9 points above its cost of capital (6.9% WACC).
Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥3.27B | CN¥3.02B | CN¥2.56B | CN¥1.93B | CN¥1.79B |
| Revenue growth | — | +18% | +33% | +8% | — |
| Gross profit | CN¥2.06B | CN¥1.83B | CN¥1.52B | CN¥1.29B | CN¥1.24B |
| EBITDA | n/a | CN¥832M | CN¥666M | CN¥490M | CN¥386M |
| Net income | CN¥617M | CN¥632M | CN¥508M | CN¥383M | CN¥273M |
| Free cash flow | CN¥203M | CN¥128M | CN¥34.8M | CN¥157M | CN¥143M |
| Capital expenditure | CN¥170M | CN¥287M | CN¥263M | CN¥132M | CN¥178M |
| Total debt | CN¥964M | CN¥774M | CN¥482M | CN¥244M | CN¥196M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Jolly Pharmaceutical 300181.SZ | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% |
| Shijiazhuang Yiling Pharmaceutical 002603.SZ | $3.83B | -7% | +32% | 21% | 17.5× | -3.9% |
| Tasly Pharmaceutical 600535.SS | $3.19B | -2% | -4% | 19% | 16.7× | -7.5% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 300181.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.1% | -1.8% | 8th lowest of 20 |
| 6-month return | -14.7% | -17.3% | 10th highest of 20 |
| Distance from 52-week high | -32.2% | -42.5% | 7th highest of 20 |
| Revenue growth (TTM) | +16.6% | +9.2% | 6th highest of 18 |
| Operating margin | 19.7% | -1.9% | 3rd highest of 18 |
| Forward P/E | 13.0× | 20.4× | 5th cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | 3.9% | 1.1% | 4th most demanding of 9 |
| Growth delivered (Del g) | +22.8% | +11.3% | 2nd highest of 9 |
| Hurdle (Req g minus delivered) | -18.9 pp | -10.4 pp | 3rd least demanding of 9 |
| ROIC minus cost of capital | +6.9 pp | -5.9 pp | 3rd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Jolly Pharmaceutical 300181.SZ | China | $1.34B | -15% | +17% | 20% | 13.0× | 3.9% | +22.8% |
| Nanobiotix NANO.PA | France | $1.35B | -32% | -77% | -392% | n/a | n/a | n/a |
| OliX Pharmaceuticals 226950.KS | South Korea | $1.35B | -51% | +27% | -384% | n/a | n/a | n/a |
| Zhejiang Hisoar Pharmaceutical 002099.SZ | China | $1.33B | -2% | +9% | -13% | n/a | n/a | n/a |
| Celltrion Pharm 068760.KS | South Korea | $1.33B | -23% | +16% | 12% | n/a | 10.2% | +18.1% |
| Shanghai OPM Biosciences 688293.SS | China | $1.32B | +36% | +133% | 11% | 48.6× | 25.9% | +23.1% |
| Windward Bio WWB | United States | $1.31B | n/a | n/a | n/a | n/a | n/a | n/a |
| MannKind MNKD | United States | $1.31B | +25% | +32% | -2% | 174.4× | n/a | n/a |
| Innoviva INVA | United States | $1.31B | -17% | +12% | 38% | 9.5× | -17.2% | +3.9% |
| Ocular Therapeutix OCUL | United States | $1.31B | -26% | -10% | -681% | n/a | n/a | n/a |
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.39B | -19% | +1% | 19% | 12.1× | -9.6% | +4.6% |
| LB Pharmaceuticals LBRX | United States | $1.30B | +43% | n/a | n/a | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.30B | -24% | +2% | -2% | 60.7× | n/a | n/a |
| Zhejiang Xianju Pharmaceutical 002332.SZ | China | $1.28B | -1% | +8% | 11% | 17.7× | -0.4% | -1.3% |
| Damora Therapeutics DMRA | United States | $1.42B | -5% | n/a | n/a | n/a | n/a | n/a |
| Nippon Shinyaku 4516.T | Japan | $1.42B | -20% | +18% | 18% | 7.9× | -18.1% | +7.0% |
| Amphastar Pharmaceuticals AMPH | United States | $1.27B | +64% | +3% | 19% | 9.1× | 2.5% | +15.5% |
| Marksans Pharma MARKSANS.NS | India | $1.43B | +36% | +24% | 20% | 23.2× | 31.0% | +16.6% |
| Voronoi 310210.KS | South Korea | $1.43B | -62% | -100% | -438,152% | n/a | n/a | n/a |
| Mezzion Pharma 140410.KS | South Korea | $1.43B | -15% | +13% | -211% | n/a | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.26B | -41% | -24% | -51% | 522.3× | n/a | n/a |